---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-11T08:50:23.821492'
end_time: '2026-02-11T08:54:40.557295'
duration_seconds: 256.74
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: BCS1L
  gene_symbol: BCS1L
  uniprot_accession: Q9Y276
  protein_description: 'RecName: Full=Mitochondrial chaperone BCS1 {ECO:0000303|PubMed:9878253};
    Short=h-BCS1; EC=3.6.1.- {ECO:0000250|UniProtKB:P32839}; AltName: Full=BCS1-like
    protein;'
  gene_info: Name=BCS1L; Synonyms=BCS1 {ECO:0000303|PubMed:9878253};
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the AAA ATPase family. BCS1 subfamily.
  protein_domains: AAA+_ATPase. (IPR003593); AAA_lid_BCS1. (IPR057495); ATPase_AAA_core.
    (IPR003959); ATPase_AAA_CS. (IPR003960); BCS1_N. (IPR014851)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 14
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9Y276
- **Protein Description:** RecName: Full=Mitochondrial chaperone BCS1 {ECO:0000303|PubMed:9878253}; Short=h-BCS1; EC=3.6.1.- {ECO:0000250|UniProtKB:P32839}; AltName: Full=BCS1-like protein;
- **Gene Information:** Name=BCS1L; Synonyms=BCS1 {ECO:0000303|PubMed:9878253};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the AAA ATPase family. BCS1 subfamily.
- **Key Domains:** AAA+_ATPase. (IPR003593); AAA_lid_BCS1. (IPR057495); ATPase_AAA_core. (IPR003959); ATPase_AAA_CS. (IPR003960); BCS1_N. (IPR014851)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BCS1L" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BCS1L' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BCS1L** (gene ID: BCS1L, UniProt: Q9Y276) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9Y276
- **Protein Description:** RecName: Full=Mitochondrial chaperone BCS1 {ECO:0000303|PubMed:9878253}; Short=h-BCS1; EC=3.6.1.- {ECO:0000250|UniProtKB:P32839}; AltName: Full=BCS1-like protein;
- **Gene Information:** Name=BCS1L; Synonyms=BCS1 {ECO:0000303|PubMed:9878253};
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the AAA ATPase family. BCS1 subfamily.
- **Key Domains:** AAA+_ATPase. (IPR003593); AAA_lid_BCS1. (IPR057495); ATPase_AAA_core. (IPR003959); ATPase_AAA_CS. (IPR003960); BCS1_N. (IPR014851)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "BCS1L" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'BCS1L' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **BCS1L** (gene ID: BCS1L, UniProt: Q9Y276) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan status: Objectives 1–6 were addressed via targeted literature search and evidence extraction; key recent (2023–2024) advances and foundational mechanisms were compiled, and a summary artifact was prepared. The final objective is fulfilled below with a comprehensive, cited report.

Comprehensive research report: Human BCS1L (UniProt Q9Y276)

Gene/protein verification and identity
- Symbol/gene name: BCS1L (also known as BCS1). Organism: Homo sapiens. Protein: mitochondrial chaperone/assembly factor BCS1L, a member of the AAA+ ATPase family, BCS1 subfamily, with an N-terminal transmembrane segment, a BCS1-specific middle domain, and a C‑terminal AAA ATPase domain. These features align with UniProt Q9Y276 and literature describing a heptameric, inner-membrane-anchored AAA+ ATPase that powers client translocation for complex III assembly (notably UQCRFS1/Rieske). (ros2025bluntingmycfunction pages 11-16, ros2025bluntingmycfunction pages 7-11)

Key concepts and definitions (current understanding)
- Primary role: BCS1L is an essential mitochondrial complex III (cytochrome bc1) assembly factor. It functions as an ATP-driven translocase/chaperone to move the fully folded Rieske iron–sulfur protein (RISP; UQCRFS1) from the matrix side into the intermembrane space (IMS) and deliver it to pre-complex III for maturation into a catalytically competent dimer. This step is required to complete CIII biogenesis and enable the Q-cycle of electron transfer from ubiquinol to cytochrome c. (ros2025bluntingmycfunction pages 11-16, ros2025bluntingmycfunction pages 7-11, ros2025bluntingmycfunction pages 16-19)
- Molecular mechanism: Recent cryo-EM–guided models indicate an ATP/ADP cycling “airlock”-like mechanism. ATP binding opens a cavity to accommodate the folded, Fe2S2-containing UQCRFS1; ATP hydrolysis drives conformational changes that gate and release the client to the IMS while preserving membrane integrity. BCS1L thus acts as an ATP-fueled transmembrane protein translocase specific for the Rieske subunit. (ros2025bluntingmycfunction pages 11-16)
- Subcellular localization and assembly state: BCS1L is embedded in the mitochondrial inner membrane via its N-terminal TM segment and assembles into a heptameric AAA+ ring that operates on the matrix side to engage folded UQCRFS1 before transferring it across/into the IMS-facing side of pre-complex III. (ros2025bluntingmycfunction pages 11-16)

Pathway context and interacting components
- Respiratory chain context: CIII is an 11-subunit dimeric complex that re-oxidizes ubiquinol (QH2) and reduces cytochrome c as part of the Q-cycle. Correct insertion and processing of the Rieske iron–sulfur protein (UQCRFS1) is a defining late step in CIII assembly that depends on BCS1L function. Perturbation of BCS1L impairs CIII assembly/activity and disrupts electron transfer, with downstream bioenergetic and metabolic consequences. (ros2025bluntingmycfunction pages 7-11)

Recent developments and latest research (2023–2024 priority)
- Mechanistic/structural advances: Contemporary structural work summarized in 2024–2025 sources proposes the ATP-coupled “airlock” model for BCS1L’s translocation of folded UQCRFS1, integrating cryo-EM snapshots of ATP- versus ADP-bound states with a gated client-handling cycle. These updates refine the classical view of BCS1L as an AAA+ chaperone into a specialized transmembrane protein translocase for a folded cofactor-containing substrate. (ros2025bluntingmycfunction pages 11-16) [Mechanism referenced therein; see also Nature Communications 2023 DOI: https://doi.org/10.1038/s41467-023-41806-5]
- Preclinical gene therapy in Bcs1l p.S78G mice (GRACILE model): In complex III–deficient Bcs1l p.S78G knock-in mice, a single intraperitoneal injection of rAAV expressing wild-type Bcs1l under a hepatocyte-specific promoter prevented hepatopathy, restored hepatic complex III assembly/activity, improved hypoglycemia and growth, normalized liver fuel use, and approximately doubled median survival, despite continued extrahepatic disease. Reported data include ~15-fold hepatic Bcs1l mRNA induction, restoration of hepatic complex III activity to ~74% of wild-type, and median survival around 58 days for AAT-driven hepatic expression cohorts. rAAV episomal dilution limited durability; PiggyBac-aided integration raised later hepatic expression but did not further extend survival. (bioRxiv Nov 2024, https://doi.org/10.1101/2024.09.23.612616; 2025 preprint, https://doi.org/10.1101/2025.09.23.677965) (banerjee2024hepaticmitochondrialrespiration pages 1-4, banerjee2025hepaticgenereplacement pages 1-5, banerjee2025hepaticgenereplacement pages 5-8)
- Thermoregulation insight and AOX rescue: The same GRACILE model revealed hypothermia, inflamed/inactive brown adipose tissue, and sensory innervation defects; increasing cellular respiration with a transgenic alternative oxidase (AOX) prevented hypothermia. Housing at thermoneutrality (35°C) alleviated metabolic stress and hepatocyte senescence, highlighting systemic physiology secondary to hepatic respiratory dysfunction. (bioRxiv Nov 2024, https://doi.org/10.1101/2024.09.23.612616) (banerjee2024hepaticmitochondrialrespiration pages 1-4)

Human genetics, phenotypes, and disease spectrum
- Spectrum of BCS1L-related disease: Pathogenic variants in BCS1L are among the most common nuclear causes of mitochondrial complex III deficiency. Clinical phenotypes include GRACILE syndrome—a severe neonatal disorder caused by a homozygous Finnish founder mutation c.A232G (p.Ser78Gly)—and Björnstad syndrome, among others, with heterogeneous systemic involvement. (ros2025bluntingmycfunction pages 16-19)
- GRACILE syndrome features: Growth restriction, lactic acidosis, hepatic iron overload/hepatopathy, proximal tubulopathy, hypoglycemia, and early death characterize the severe end of the spectrum; mouse knock-in models recapitulate postnatal-onset decline in hepatic complex III assembly and bioenergetics, establishing a presymptomatic therapeutic window. Diet and gene-modulatory interventions (e.g., ketogenic diet, MYC modulation) have shown disease-modifying effects in mice, underscoring pathway tractability. (ros2025bluntingmycfunction pages 16-19, ros2025bluntingmycfunction pages 7-11)

Current applications and real-world implementations
- Preclinical gene replacement: Hepatocyte-directed rAAV Bcs1l replacement constitutes a concrete, reproducible application with disease-modifying effects in a multiorgan mitochondrial disease model. Benefits include prevention of hepatopathy, restoration of hepatic complex III function, improved systemic metabolism, and extended survival. Limitations include incomplete correction in extrahepatic tissues and waning expression from episomal vectors. (bioRxiv Nov 2024, https://doi.org/10.1101/2024.09.23.612616; 2025 preprint, https://doi.org/10.1101/2025.09.23.677965) (banerjee2024hepaticmitochondrialrespiration pages 1-4, banerjee2025hepaticgenereplacement pages 1-5, banerjee2025hepaticgenereplacement pages 5-8)
- Systems physiology insights: Thermoregulation defects in Bcs1l p.S78G mice were prevented by AOX-driven respiration and improved by thermoneutral housing, informing supportive care hypotheses for mitochondrial disease (e.g., careful temperature management). (bioRxiv Nov 2024, https://doi.org/10.1101/2024.09.23.612616) (banerjee2024hepaticmitochondrialrespiration pages 1-4)

Expert opinions and authoritative synthesis
- State-of-the-art view: BCS1L is best understood as a dedicated AAA+ protein translocase that recognizes and translocates folded, cofactor-loaded UQCRFS1 across/into the IMS side of pre-complex III. This specialized role distinguishes it from general chaperones and positions it as the key gatekeeper of a late, rate-determining assembly step in CIII biogenesis. Disruption leads to a cascade of tissue-selective vulnerabilities, with the liver as a critical hub of systemic energy homeostasis in severe pediatric presentations. (ros2025bluntingmycfunction pages 11-16, ros2025bluntingmycfunction pages 7-11, ros2025bluntingmycfunction pages 16-19)
- Translational outlook: The hepatocyte-first gene replacement strategy demonstrates meaningful disease modification and suggests that multi-tissue or sequential organ-targeted delivery—or durable genomic integration—may be required for sustained benefit in systemic disease. Modulating downstream stress responses (e.g., MYC activity) and environmental variables (thermoneutrality) may further expand therapeutic windows. (banerjee2024hepaticmitochondrialrespiration pages 1-4, banerjee2025hepaticgenereplacement pages 5-8, ros2025bluntingmycfunction pages 7-11)

Relevant statistics and data points (from recent studies)
- Hepatocyte-directed rAAV Bcs1l in Bcs1l p.S78G mice: ~15-fold hepatic Bcs1l mRNA at postnatal day 28; hepatic complex III activity restored to ~74% of WT; prevention of hepatopathy; improved glucose homeostasis and growth; median survival extended to ~58 days (AAT promoter cohort), with broader expression (CAG) modestly increasing survival further. (banerjee2025hepaticgenereplacement pages 1-5, banerjee2025hepaticgenereplacement pages 5-8)
- Thermoregulation: AOX transgene normalized core temperature in CIII-deficient mice; thermoneutral housing (35°C) relieved metabolic stress and hepatocyte senescence, implicating hepatic respiration in whole-body temperature control. (banerjee2024hepaticmitochondrialrespiration pages 1-4)

Embedded quick-reference artifact
| Aspect | Summary | Evidence (Context IDs) |
|---|---|---|
| Identity / Family / Domains | AAA+ ATPase, BCS1 subfamily; N-terminal transmembrane helix, BCS1-specific domain, C-terminal AAA ATPase domain. | (ros2025bluntingmycfunction pages 11-16, ros2025bluntingmycfunction pages 7-11) |
| Subcellular localization | Mitochondrial inner membrane; assembles as a heptameric ring that spans matrix/inner-membrane and operates to move clients into the intermembrane space. | (ros2025bluntingmycfunction pages 11-16, ros2025bluntingmycfunction pages 7-11) |
| Primary function | ATP-driven translocase/chaperone that translocates the folded Rieske Fe-S protein (UQCRFS1 / RISP) from the matrix into the IMS for incorporation into pre-complex III. | (ros2025bluntingmycfunction pages 11-16, ros2025bluntingmycfunction pages 7-11, ros2025bluntingmycfunction pages 16-19) |
| Mechanism | ATP/ADP-dependent conformational cycle; recent cryo-EM supports an "airlock"-like gating mechanism that accepts folded RISP in the ATP-bound state and releases it upon hydrolysis. | (ros2025bluntingmycfunction pages 11-16) |
| Pathway context | Essential assembly factor for mitochondrial Complex III (cytochrome bc1); required for formation of catalytically competent CIII and thus for the Q-cycle electron transfer. | (ros2025bluntingmycfunction pages 7-11, banerjee2024hepaticmitochondrialrespiration pages 1-4) |
| Human disease associations | Pathogenic variants cause a spectrum including GRACILE syndrome (founder p.S78G), Björnstad syndrome, and heterogeneous phenotypes from CIII deficiency. | (ros2025bluntingmycfunction pages 16-19, ros2025bluntingmycfunction pages 7-11) |
| Recent advances (2023–2024) | Preclinical Bcs1l p.S78G mouse studies show hepatocyte-targeted rAAV Bcs1l restores hepatic CIII and metabolism, improves thermoregulation (AOX studies) and can ~double survival in treated cohorts. | (banerjee2024hepaticmitochondrialrespiration pages 1-4, banerjee2025hepaticgenereplacement pages 1-5, banerjee2025hepaticgenereplacement pages 14-17) |
| Real-world implementations | Preclinical rAAV-based, hepatocyte-directed gene replacement (AAT promoter; CAG tested) and PiggyBac co-integration strategies have been applied in mouse GRACILE models. | (banerjee2025hepaticgenereplacement pages 1-5, banerjee2025hepaticgenereplacement pages 5-8, banerjee2024hepaticmitochondrialrespiration pages 1-4) |
| Key data points / statistics | AAT-Bcs1l hepatocyte rescue: ~15-fold hepatic Bcs1l mRNA at P28; hepatic CIII activity restored to ~74% of WT; median survival extended to ~58 days in treated mice. | (banerjee2025hepaticgenereplacement pages 1-5, banerjee2025hepaticgenereplacement pages 5-8) |
| Open questions / challenges | Extrahepatic disease progression limits lifespan despite hepatic rescue; rAAV episomal dilution limits durability—multi-tissue or durable delivery approaches needed. | (banerjee2025hepaticgenereplacement pages 5-8, banerjee2025hepaticgenereplacement pages 14-17) |


*Table: A concise, evidence-linked summary table of BCS1L biological identity, mechanism, disease links, recent preclinical therapeutic advances, and outstanding challenges; useful as a quick-reference for researchers and clinicians (context IDs cite the gathered evidence).*

Notes on verification and ambiguity
- The symbol BCS1L unambiguously corresponds to the human mitochondrial assembly factor BCS1L described here; no conflicting gene of the same symbol was identified in the evidence set. Domain architecture and family classification (AAA+ ATPase, BCS1 subfamily) match UniProt Q9Y276 and are consistent with recent mechanistic literature. (ros2025bluntingmycfunction pages 11-16)

References with URLs and dates (where available)
- Hepatocyte-directed gene replacement and thermoregulation in Bcs1l p.S78G mice: bioRxiv, posted Nov 2024. https://doi.org/10.1101/2024.09.23.612616 (banerjee2024hepaticmitochondrialrespiration pages 1-4)
- Hepatic gene replacement extends survival, restores CIII activity and metabolism in GRACILE model: preprint, posted Sep 2025. https://doi.org/10.1101/2025.09.23.677965 (banerjee2025hepaticgenereplacement pages 1-5, banerjee2025hepaticgenereplacement pages 14-17, banerjee2025hepaticgenereplacement pages 5-8)
- Mechanistic summary of BCS1L as heptameric AAA+ ATPase/translocase for folded UQCRFS1 and disease spectrum overview: 2025 source summarizing 2023–2024 structural advances and clinical entities. (ros2025bluntingmycfunction pages 11-16, ros2025bluntingmycfunction pages 16-19, ros2025bluntingmycfunction pages 7-11)

Citations
- Mechanism, domains, heptameric assembly, UQCRFS1 client and “airlock” model: (ros2025bluntingmycfunction pages 11-16)
- CIII composition/function context and UQCRFS1 role: (ros2025bluntingmycfunction pages 7-11)
- Disease spectrum including GRACILE (p.S78G) and Björnstad; mouse model features and presymptomatic window; dietary/MYC modulation context: (ros2025bluntingmycfunction pages 16-19, ros2025bluntingmycfunction pages 7-11)
- rAAV hepatocyte Bcs1l rescue: prevention of hepatopathy, restored hepatic CIII function, survival extension, durability limits and PiggyBac findings: (banerjee2024hepaticmitochondrialrespiration pages 1-4, banerjee2025hepaticgenereplacement pages 1-5, banerjee2025hepaticgenereplacement pages 5-8)
- Thermoregulation and AOX rescue; thermoneutrality effects: (banerjee2024hepaticmitochondrialrespiration pages 1-4)

References

1. (ros2025bluntingmycfunction pages 11-16): O Ros. Blunting myc function in mitochondrial complex iii deficient mice with a hypomorphic myc allele. Unknown journal, 2025.

2. (ros2025bluntingmycfunction pages 7-11): O Ros. Blunting myc function in mitochondrial complex iii deficient mice with a hypomorphic myc allele. Unknown journal, 2025.

3. (ros2025bluntingmycfunction pages 16-19): O Ros. Blunting myc function in mitochondrial complex iii deficient mice with a hypomorphic myc allele. Unknown journal, 2025.

4. (banerjee2024hepaticmitochondrialrespiration pages 1-4): Rishi Banerjee, Divya Upadhyay, Tomáš Zarybnický, Christa Kietz, Satu Kuure, Vineta Fellman, Janne Purhonen, and Jukka Kallijärvi. Hepatic mitochondrial respiration is crucial for euthermia in complex iii-deficient mice with impaired brown adipose tissue thermogenesis. bioRxiv, Nov 2024. URL: https://doi.org/10.1101/2024.09.23.612616, doi:10.1101/2024.09.23.612616. This article has 2 citations and is from a poor quality or predatory journal.

5. (banerjee2025hepaticgenereplacement pages 1-5): Rishi Banerjee, Janne Purhonen, Nasrin Sultana, Christa Kietz, Vineta Fellman, and Jukka Kallijärvi. Hepatic gene replacement restores energy metabolism and doubles the survival in mouse model of gracile syndrome, a neonatal mitochondrial disease. BioRxiv, Sep 2025. URL: https://doi.org/10.1101/2025.09.23.677965, doi:10.1101/2025.09.23.677965. This article has 0 citations and is from a poor quality or predatory journal.

6. (banerjee2025hepaticgenereplacement pages 5-8): Rishi Banerjee, Janne Purhonen, Nasrin Sultana, Christa Kietz, Vineta Fellman, and Jukka Kallijärvi. Hepatic gene replacement restores energy metabolism and doubles the survival in mouse model of gracile syndrome, a neonatal mitochondrial disease. BioRxiv, Sep 2025. URL: https://doi.org/10.1101/2025.09.23.677965, doi:10.1101/2025.09.23.677965. This article has 0 citations and is from a poor quality or predatory journal.

7. (banerjee2025hepaticgenereplacement pages 14-17): Rishi Banerjee, Janne Purhonen, Nasrin Sultana, Christa Kietz, Vineta Fellman, and Jukka Kallijärvi. Hepatic gene replacement restores energy metabolism and doubles the survival in mouse model of gracile syndrome, a neonatal mitochondrial disease. BioRxiv, Sep 2025. URL: https://doi.org/10.1101/2025.09.23.677965, doi:10.1101/2025.09.23.677965. This article has 0 citations and is from a poor quality or predatory journal.

## Citations

1. ros2025bluntingmycfunction pages 11-16
2. ros2025bluntingmycfunction pages 7-11
3. banerjee2024hepaticmitochondrialrespiration pages 1-4
4. ros2025bluntingmycfunction pages 16-19
5. banerjee2025hepaticgenereplacement pages 1-5
6. banerjee2025hepaticgenereplacement pages 5-8
7. banerjee2025hepaticgenereplacement pages 14-17
8. Mechanism referenced therein; see also Nature Communications 2023 DOI: https://doi.org/10.1038/s41467-023-41806-5
9. https://doi.org/10.1038/s41467-023-41806-5]
10. https://doi.org/10.1101/2024.09.23.612616;
11. https://doi.org/10.1101/2025.09.23.677965
12. https://doi.org/10.1101/2024.09.23.612616
13. https://doi.org/10.1101/2024.09.23.612616,
14. https://doi.org/10.1101/2025.09.23.677965,